Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116437 | 0.86 | PTGS2 (0.66) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL1444267 | 0.81 | GAA (0.61) | ALDH1A1MAPTPOLBLMNAGAA | |
| SCHEMBL2446705 | 0.81 | MAPT (0.47) | ALDH1A1CYP2C9CYP2C19MAPTMEN1 | |
| SCHEMBL10434827 | 0.81 | MAPT (0.44) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL3167492 | 0.80 | PSEN1 (0.45) | ALDH1A1CYP2C9CYP2C19MAPTPOLB | |
| SCHEMBL3170416 | 0.80 | MAPT (0.48) | ALDH1A1MAPTMEN1KMT2AL3MBTL1 | |
| SCHEMBL544051 | 0.80 | ALOX15 (0.63) | PTGS2ALDH1A1MAPTPOLBMEN1 | |
| SCHEMBL3169853 | 0.80 | ALOX15 (0.42) | ALDH1A1CYP2C9CYP2C19MAPTL3MBTL1 | |
| SCHEMBL17365269 | 0.80 | PTGS2 (0.60) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT | |
| SCHEMBL12061812 | 0.80 | GAA (0.66) | PTGS2ALDH1A1CYP2C9CYP2C19MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116234546-A | GPX4 inhibitors, pharmaceutical compositions thereof and their use in the treatment of GPX4 mediated diseases | 嘉兴优博生物技术有限公司 | 2023-06-06 | — | — | CN | claimed |
| WO-2021183702-A1 | GPX4 INHIBITORS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE FOR TREATING GPX4-MEDIATED DISEASES | EUBULUS BIOTHERAPEUTICS INC. (CN) | 2021-09-16 | — | — | WO | claimed |
| EP-3241829-B1 | HETEROARYLPIPERIDINE AND -PIPERAZINE DERIVATIVES AS FUNGICIDES | BAYER CROPSCIENCE AG (DE) | 2020-12-23 | — | — | EP | claimed |
| EP-2915186-B1 | FORMULATIONS OF SOLUTIONS AND PROCESSES FOR FORMING A SUBSTRATE INCLUDING AN ARSENIC DOPANT | VERSUM MAT US LLC (US) | 2020-10-28 | — | — | EP | claimed |
| US-9006266-B2 | Heteroarylpiperidine and -piperazine derivatives as fungicides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-14 | — | — | US | claimed |
| US-7652044-B2 | P-38 inhibitors | NOVARTIS A.G. (CH) | 2010-01-26 | — | — | US | claimed |
| US-7371747-B2 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA & CO. (CA) | 2008-05-13 | — | — | US | claimed |
| EP-1446115-B1 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA LTD (CA) | 2008-02-27 | — | — | EP | claimed |
| US-7329654-B2 | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-12 | — | — | US | claimed |
| WO-2006078698-A1 | 2-IMIDAZOLONE AND 2-IMIDAZOLIDINONE HETEROCYCLIC INHIBITORS OF TYROSINE PHOSPHATASES | CENGENT THERAPEUTICS, INC. (US) | 2006-07-27 | — | — | WO | claimed |
| US-20050014941-A1 | Cyanoalkylamino derivatives as protease inhibitors | MERCK FROSST CANADA LTD. (CA) | 2005-01-20 | — | — | US | claimed |
| WO-2005000298-A2 | 5-MEMBERED HETEROCYCLE-BASED P-38 INHIBITORS | NOVARTIS AG (CH) | 2005-01-06 | — | — | WO | claimed |
| US-20040254236-A1 | P-38 inhibitors | NOVARTIS AG (CH) | 2004-12-16 | — | — | US | claimed |
| EP-1467998-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | Ortho-Mcneil Pharmaceutical, Inc. (US) | 2004-10-20 | — | — | EP | claimed |
| EP-1446115-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | Merck Frosst Canada & Co. (CA) | 2004-08-18 | — | — | EP | claimed |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-20 | — | — | US | claimed |
| WO-2003053977-A1 | TETRACYCLIC HETEROCOMPOUNDS AS ESTROGEN RECEPTOR MODULATORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2003-07-03 | — | — | WO | claimed |
| WO-2003041649-A2 | CYANOALKYLAMINO DERIVATIVES AS PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2003-05-22 | — | — | WO | claimed |
| EP-0239874-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their application | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-10-07 | — | — | EP | claimed |
| EP-0230242-A2 | Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-07-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254236-A1 | P-38 inhibitors | MAPK8, MAP3K8, MAPK1 | PTGS2 686/4885ALDH1A1 3687/4885CYP2C9 3763/4885 |
| US-20050014941-A1 | Cyanoalkylamino derivatives as protease inhibitors | CTSB, CTSK, CTSS | PTGS2 2511/4885ALDH1A1 3183/4885CYP2C9 2016/4885 |
| US-20030216463-A1 | Novel heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators | GPER1, ESR2, FSHR | PTGS2 437/4885ALDH1A1 2801/4885CYP2C9 1982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.